Dordaviprone Approved for H3 K27M-mutated Diffuse Midline Glioma
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline glioma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso)...